+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cellular & Gene Therapy CDMO Market - Global Forecast 2026-2032- Product Image
Cellular & Gene Therapy CDMO Market - Global Forecast 2026-2032- Product Image
Sale

Cellular & Gene Therapy CDMO Market - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6280871
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Cellular & Gene Therapy CDMO: Executive Summary

Cellular and gene therapy contract development and manufacturing organizations (CDMOs) support developers with process development, analytical testing, viral-vector production, cell processing, fill-finish, quality systems, and regulatory readiness. The market is shaped by technically demanding products, specialized facilities, stringent contamination controls, complex supply chains, and the need to transition reliably from clinical material to commercial manufacturing.

Manufacturing Complexity Is Reshaping CDMO Strategy

The landscape is shifting from conventional outsourced production toward integrated, platform-based services that connect development, testing, manufacturing, and regulatory support. Key priorities include closed and automated processing, scalable viral-vector platforms, flexible facilities, robust comparability plans, and stronger chain-of-identity and chain-of-custody controls. Developers are also placing greater emphasis on technology transfer, batch consistency, raw-material security, and manufacturing approaches that can accommodate both autologous and allogeneic therapies.

Artificial Intelligence Strengthens Development and Operations

Artificial intelligence can support process optimization by identifying relationships among process parameters, analytical results, and product-quality attributes. It can also assist deviation investigation, predictive maintenance, scheduling, documentation review, and supply-chain monitoring. Its practical value depends on validated data pipelines, traceable model outputs, cybersecurity, human oversight, and compliance with applicable quality and regulatory requirements. Adoption is therefore most credible where AI augments established workflows rather than replacing qualified scientific and quality decisions.

Regional Insights: Capacity, Regulation, and Supply Chains

North America combines advanced clinical ecosystems, specialized manufacturing capabilities, and deep regulatory experience, while Latin America is developing supporting capabilities amid varied regulatory and infrastructure conditions. Europe benefits from strong scientific networks and harmonized elements within the European Union, although national implementation and capacity considerations remain relevant. The Middle East is pursuing biotechnology and healthcare diversification, and Africa’s opportunity is linked to workforce development, technology transfer, and resilient local supply chains. Asia-Pacific includes mature biomanufacturing centers alongside rapidly developing markets, creating a diverse landscape for partnerships, localization, and cross-border technology transfer.

Group Insights: Cooperation Shapes Capability Building

ASEAN markets are relevant to regional manufacturing networks and workforce development, while BRICS members span substantial scientific, industrial, and healthcare capabilities with differing regulatory environments. The European Union provides a coordinated policy context for cross-border development, complemented by national authorities and specialized production hubs. G7 economies contribute established research, financing, and regulatory capabilities. GCC countries are investing in healthcare and biotechnology infrastructure, while NATO members provide a broad context for resilience, security of supply, and advanced life-science collaboration.

Country Insights: Diverse Paths to Cell and Gene Therapy Capacity

The United States and Canada offer mature research, clinical, and regulatory ecosystems. Germany, France, Italy, Spain, and the United Kingdom combine strong biomedical capabilities with distinct national approval, reimbursement, and manufacturing pathways. China, Japan, South Korea, India, and Australia are expanding or refining specialized capabilities across research, clinical translation, and biomanufacturing. Brazil and Mexico are important Latin American markets for healthcare and biotechnology development, while Russia’s capabilities and access conditions are influenced by regulatory, investment, and international operating factors. Across all countries, workforce depth, quality infrastructure, raw-material access, and technology-transfer execution remain decisive.

Priorities for Leaders: Build Flexible, Qualified, and Data-Ready Operations

Industry leaders should align facility design with the specific requirements of viral vectors, engineered cells, and patient-specific workflows rather than relying on a single manufacturing model. They should qualify critical suppliers, establish dual-source strategies where practical, and invest early in analytical methods, comparability, and digital batch records. Partnerships should be governed by clear technology-transfer responsibilities, quality agreements, change-control procedures, and contingency plans. Leaders should also define responsible AI policies, validate high-value use cases, and measure performance through indicators such as batch success, deviation closure, transfer timelines, turnaround time, and inspection readiness.

Research Methodology: Structured Analysis of the CDMO Ecosystem

This executive summary uses the defined cellular and gene therapy CDMO scope and organizes the analysis around manufacturing services, process and analytical capabilities, quality and regulatory requirements, supply-chain resilience, digitalization, regional conditions, country environments, and strategic priorities. Insights are presented qualitatively and are limited to established industry characteristics and the specified geographic groupings. No market estimates, market shares, forecasts, or company-specific claims are used.

Conclusion: Resilience and Execution Will Differentiate Providers

Cellular and gene therapy CDMOs operate at the intersection of advanced biology, precision manufacturing, clinical urgency, and rigorous quality control. Sustainable progress will depend on integrated development-to-manufacturing services, dependable materials and logistics, scalable and closed processes, strong analytical foundations, and disciplined technology transfer. Providers and sponsors that combine scientific expertise with operational resilience, regulatory readiness, and responsible digital adoption will be best positioned to support the next stage of therapy development.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Cellular & Gene Therapy CDMO Market, by Therapeutic Modality
7.1. Introduction
7.2. Cell Therapy
7.2.1. Allogeneic
7.2.2. Autologous
7.2.3. Engineered Immune Cell Therapies
7.3. Gene Therapy
7.3.1. Cell Therapy
7.3.2. Combined Cell Gene Products
7.3.3. Gene Modified Cell Therapy
7.3.4. Non Viral Gene Therapy
7.3.5. Viral Vector Gene Therapy
7.4. Nucleic Acid Modalities
7.4.1. mRNA Therapies
7.4.2. Oligonucleotide Approaches
7.4.3. Plasmid DNA
8. Cellular & Gene Therapy CDMO Market, by Service Offering
8.1. Introduction
8.2. Analytical And Quality Control
8.2.1. Method Validation
8.2.2. Release Testing
8.2.3. Stability Testing
8.3. Cell Banking And Cryopreservation
8.3.1. Cell Banking
8.3.2. Master And Working Cell Banks
8.4. Fill Finish
8.4.1. Aseptic Fill Finish
8.4.2. Cryopreservation And Cryo Bags
8.4.3. Lyophilization
8.5. Manufacturing
8.5.1. Campaign Manufacturing
8.5.2. Clinical Manufacturing
8.5.3. Commercial Manufacturing
8.6. Process Development
8.6.1. Analytical Method Development
8.6.2. Downstream Process Development
8.6.3. Formulation Development
8.6.4. Tech Transfer
8.6.5. Upstream Process Development
9. Cellular & Gene Therapy CDMO Market, by Technology Platform
9.1. Introduction
9.2. Cell Culture Platforms
9.2.1. Fixed Bed And Packed Bed Systems
9.2.2. Single Use Bioreactors
9.2.3. Suspension And Adherent Platforms
9.3. Gene Editing Tools
9.3.1. CRISPR
9.3.2. TALEN
9.3.3. Zinc Finger Nucleases
9.4. Non Viral Platforms
9.4.1. mRNA Delivery
9.4.2. Nanoparticle Delivery
9.4.3. Plasmid And DNA
9.5. Viral Vectors
9.5.1. AAV
9.5.2. Adenovirus
9.5.3. Lentivirus
9.5.4. Retrovirus
10. Cellular & Gene Therapy CDMO Market, by Cell Source
10.1. Introduction
10.2. Allogeneic Cells
10.3. Autologous Cells
10.4. Immune Cells
10.4.1. Dendritic Cells
10.4.2. NK Cells
10.4.3. T Cells
10.5. Stem Cells
10.5.1. Hematopoietic Stem Cells
10.5.2. Pluripotent Stem Cells
11. Cellular & Gene Therapy CDMO Market, by Customer Type
11.1. Introduction
11.2. Academic And Research Institutions
11.3. Clinical Treatment Centers
11.4. Large Pharmaceutical Companies
11.5. Small And Mid Size Biotech
12. Cellular & Gene Therapy CDMO Market, by Therapy Indication
12.1. Introduction
12.2. Autoimmune And Inflammatory
12.3. Cardiovascular
12.4. Neurology
12.5. Oncology
12.6. Ophthalmology
12.7. Rare Genetic Diseases
13. Cellular & Gene Therapy CDMO Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Cellular & Gene Therapy CDMO Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Cellular & Gene Therapy CDMO Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AGC Biologics A/S
17.2. BioCentriq, Inc.
17.3. Boehringer Ingelheim International GmbH
17.4. Catalent, Inc.
17.5. Cellares Corporation
17.6. Cellipont Bioservices, LLC
17.7. Charles River Laboratories International, Inc.
17.8. ElevateBio, Inc.
17.9. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
17.10. GenScript ProBio, Inc.
17.11. Kincell Bio, LLC
17.12. Lonza Group AG
17.13. Minaris Regenerative Medicine GmbH
17.14. National Resilience, Inc.
17.15. Oxford BioMedica plc
17.16. Porton Advanced Solutions Ltd.
17.17. Samsung Biologics Co., Ltd.
17.18. Thermo Fisher Scientific Inc.
17.19. VectorBuilder Inc.
17.20. WuXi Advanced Therapies Inc.
17.21. WuXi AppTec Co., Ltd.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Cellular & Gene Therapy CDMO Market, Years Considered for the Study
FIGURE 2. Global Cellular & Gene Therapy CDMO Market, Research Design
FIGURE 3. Global Cellular & Gene Therapy CDMO Market, Research Framework
FIGURE 4. Global Cellular & Gene Therapy CDMO Market, Data Triangulation
FIGURE 5. Global Cellular & Gene Therapy CDMO Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Cellular & Gene Therapy CDMO Market Size, by Therapeutic Modality, 2025 vs 2032 (%)
FIGURE 7. Global Cellular & Gene Therapy CDMO Market Size, by Therapeutic Modality, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Cellular & Gene Therapy CDMO Market Size, by Service Offering, 2025 vs 2032 (%)
FIGURE 9. Global Cellular & Gene Therapy CDMO Market Size, by Service Offering, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Cellular & Gene Therapy CDMO Market Size, by Technology Platform, 2025 vs 2032 (%)
FIGURE 11. Global Cellular & Gene Therapy CDMO Market Size, by Technology Platform, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Cellular & Gene Therapy CDMO Market Size, by Cell Source, 2025 vs 2032 (%)
FIGURE 13. Global Cellular & Gene Therapy CDMO Market Size, by Cell Source, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Cellular & Gene Therapy CDMO Market Size, by Customer Type, 2025 vs 2032 (%)
FIGURE 15. Global Cellular & Gene Therapy CDMO Market Size, by Customer Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Cellular & Gene Therapy CDMO Market Size, by Therapy Indication, 2025 vs 2032 (%)
FIGURE 17. Global Cellular & Gene Therapy CDMO Market Size, by Therapy Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Cellular & Gene Therapy CDMO Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Cellular & Gene Therapy CDMO Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Cellular & Gene Therapy CDMO Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Cellular & Gene Therapy CDMO Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Cellular & Gene Therapy CDMO Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Cellular & Gene Therapy CDMO Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Cellular & Gene Therapy CDMO Market Segmentation & Coverage
TABLE 2. Global Cellular & Gene Therapy CDMO Market Size, 2017-2032 (USD Million)
TABLE 3. Global Cellular & Gene Therapy CDMO Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 4. Global Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Allogeneic Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Allogeneic Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Allogeneic Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Autologous Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Autologous Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Autologous Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Engineered Immune Cell Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Engineered Immune Cell Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Engineered Immune Cell Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Combined Cell Gene Products Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Combined Cell Gene Products Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Combined Cell Gene Products Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Gene Modified Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Gene Modified Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Gene Modified Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Non Viral Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Non Viral Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Non Viral Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Viral Vector Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Viral Vector Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Viral Vector Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Nucleic Acid Modalities Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Nucleic Acid Modalities Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Nucleic Acid Modalities Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global mRNA Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global mRNA Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global mRNA Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Oligonucleotide Approaches Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Oligonucleotide Approaches Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Oligonucleotide Approaches Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Plasmid DNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Plasmid DNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Plasmid DNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Cellular & Gene Therapy CDMO Market Size, by Service Offering, 2017-2032 (USD Million)
TABLE 47. Global Analytical And Quality Control Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Analytical And Quality Control Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Analytical And Quality Control Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Method Validation Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Method Validation Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Method Validation Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Release Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Release Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Release Testing Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Stability Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Stability Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Stability Testing Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Cell Banking And Cryopreservation Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Cell Banking And Cryopreservation Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Cell Banking And Cryopreservation Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Cell Banking Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Cell Banking Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Cell Banking Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Master And Working Cell Banks Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Master And Working Cell Banks Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Master And Working Cell Banks Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Fill Finish Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Fill Finish Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Fill Finish Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Aseptic Fill Finish Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Aseptic Fill Finish Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Aseptic Fill Finish Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Cryopreservation And Cryo Bags Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Cryopreservation And Cryo Bags Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Cryopreservation And Cryo Bags Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Lyophilization Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Lyophilization Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Lyophilization Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Manufacturing Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Manufacturing Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Manufacturing Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Campaign Manufacturing Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Campaign Manufacturing Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Campaign Manufacturing Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Clinical Manufacturing Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Clinical Manufacturing Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Clinical Manufacturing Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Commercial Manufacturing Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Commercial Manufacturing Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Commercial Manufacturing Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global Process Development Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Global Process Development Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. Global Process Development Market Size, by Country, 2017-2032 (USD Million)
TABLE 95. Global Analytical Method Development Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Global Analytical Method Development Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. Global Analytical Method Development Market Size, by Country, 2017-2032 (USD Million)
TABLE 98. Global Downstream Process Development Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Global Downstream Process Development Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. Global Downstream Process Development Market Size, by Country, 2017-2032 (USD Million)
TABLE 101. Global Formulation Development Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Global Formulation Development Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. Global Formulation Development Market Size, by Country, 2017-2032 (USD Million)
TABLE 104. Global Tech Transfer Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Global Tech Transfer Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. Global Tech Transfer Market Size, by Country, 2017-2032 (USD Million)
TABLE 107. Global Upstream Process Development Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Global Upstream Process Development Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. Global Upstream Process Development Market Size, by Country, 2017-2032 (USD Million)
TABLE 110. Global Cellular & Gene Therapy CDMO Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 111. Global Cell Culture Platforms Market Size, by Region, 2017-2032 (USD Million)
TABLE 112. Global Cell Culture Platforms Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. Global Cell Culture Platforms Market Size, by Country, 2017-2032 (USD Million)
TABLE 114. Global Fixed Bed And Packed Bed Systems Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Global Fixed Bed And Packed Bed Systems Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. Global Fixed Bed And Packed Bed Systems Market Size, by Country, 2017-2032 (USD Million)
TABLE 117. Global Single Use Bioreactors Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. Global Single Use Bioreactors Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. Global Single Use Bioreactors Market Size, by Country, 2017-2032 (USD Million)
TABLE 120. Global Suspension And Adherent Platforms Market Size, by Region, 2017-2032 (USD Million)
TABLE 121. Global Suspension And Adherent Platforms Market Size, by Group, 2017-2032 (USD Million)
TABLE 122. Global Suspension And Adherent Platforms Market Size, by Country, 2017-2032 (USD Million)
TABLE 123. Global Gene Editing Tools Market Size, by Region, 2017-2032 (USD Million)
TABLE 124. Global Gene Editing Tools Market Size, by Group, 2017-2032 (USD Million)
TABLE 125. Global Gene Editing Tools Market Size, by Country, 2017-2032 (USD Million)
TABLE 126. Global CRISPR Market Size, by Region, 2017-2032 (USD Million)
TABLE 127. Global CRISPR Market Size, by Group, 2017-2032 (USD Million)
TABLE 128. Global CRISPR Market Size, by Country, 2017-2032 (USD Million)
TABLE 129. Global TALEN Market Size, by Region, 2017-2032 (USD Million)
TABLE 130. Global TALEN Market Size, by Group, 2017-2032 (USD Million)
TABLE 131. Global TALEN Market Size, by Country, 2017-2032 (USD Million)
TABLE 132. Global Zinc Finger Nucleases Market Size, by Region, 2017-2032 (USD Million)
TABLE 133. Global Zinc Finger Nucleases Market Size, by Group, 2017-2032 (USD Million)
TABLE 134. Global Zinc Finger Nucleases Market Size, by Country, 2017-2032 (USD Million)
TABLE 135. Global Non Viral Platforms Market Size, by Region, 2017-2032 (USD Million)
TABLE 136. Global Non Viral Platforms Market Size, by Group, 2017-2032 (USD Million)
TABLE 137. Global Non Viral Platforms Market Size, by Country, 2017-2032 (USD Million)
TABLE 138. Global mRNA Delivery Market Size, by Region, 2017-2032 (USD Million)
TABLE 139. Global mRNA Delivery Market Size, by Group, 2017-2032 (USD Million)
TABLE 140. Global mRNA Delivery Market Size, by Country, 2017-2032 (USD Million)
TABLE 141. Global Nanoparticle Delivery Market Size, by Region, 2017-2032 (USD Million)
TABLE 142. Global Nanoparticle Delivery Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. Global Nanoparticle Delivery Market Size, by Country, 2017-2032 (USD Million)
TABLE 144. Global Plasmid And DNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 145. Global Plasmid And DNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 146. Global Plasmid And DNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 147. Global Viral Vectors Market Size, by Region, 2017-2032 (USD Million)
TABLE 148. Global Viral Vectors Market Size, by Group, 2017-2032 (USD Million)
TABLE 149. Global Viral Vectors Market Size, by Country, 2017-2032 (USD Million)
TABLE 150. Global AAV Market Size, by Region, 2017-2032 (USD Million)
TABLE 151. Global AAV Market Size, by Group, 2017-2032 (USD Million)
TABLE 152. Global AAV Market Size, by Country, 2017-2032 (USD Million)
TABLE 153. Global Adenovirus Market Size, by Region, 2017-2032 (USD Million)
TABLE 154. Global Adenovirus Market Size, by Group, 2017-2032 (USD Million)
TABLE 155. Global Adenovirus Market Size, by Country, 2017-2032 (USD Million)
TABLE 156. Global Lentivirus Market Size, by Region, 2017-2032 (USD Million)
TABLE 157. Global Lentivirus Market Size, by Group, 2017-2032 (USD Million)
TABLE 158. Global Lentivirus Market Size, by Country, 2017-2032 (USD Million)
TABLE 159. Global Retrovirus Market Size, by Region, 2017-2032 (USD Million)
TABLE 160. Global Retrovirus Market Size, by Group, 2017-2032 (USD Million)
TABLE 161. Global Retrovirus Market Size, by Country, 2017-2032 (USD Million)
TABLE 162. Global Cellular & Gene Therapy CDMO Market Size, by Cell Source, 2017-2032 (USD Million)
TABLE 163. Global Allogeneic Cells Market Size, by Region, 2017-2032 (USD Million)
TABLE 164. Global Allogeneic Cells Market Size, by Group, 2017-2032 (USD Million)
TABLE 165. Global Allogeneic Cells Market Size, by Country, 2017-2032 (USD Million)
TABLE 166. Global Autologous Cells Market Size, by Region, 2017-2032 (USD Million)
TABLE 167. Global Autologous Cells Market Size, by Group, 2017-2032 (USD Million)
TABLE 168. Global Autologous Cells Market Size, by Country, 2017-2032 (USD Million)
TABLE 169. Global Immune Cells Market Size, by Region, 2017-2032 (USD Million)
TABLE 170. Global Immune Cells Market Size, by Group, 2017-2032 (USD Million)
TABLE 171. Global Immune Cells Market Size, by Country, 2017-2032 (USD Million)
TABLE 172. Global Dendritic Cells Market Size, by Region, 2017-2032 (USD Million)
TABLE 173. Global Dendritic Cells Market Size, by Group, 2017-2032 (USD Million)
TABLE 174. Global Dendritic Cells Market Size, by Country, 2017-2032 (USD Million)
TABLE 175. Global NK Cells Market Size, by Region, 2017-2032 (USD Million)
TABLE 176. Global NK Cells Market Size, by Group, 2017-2032 (USD Million)
TABLE 177. Global NK Cells Market Size, by Country, 2017-2032 (USD Million)
TABLE 178. Global T Cells Market Size, by Region, 2017-2032 (USD Million)
TABLE 179. Global T Cells Market Size, by Group, 2017-2032 (USD Million)
TABLE 180. Global T Cells Market Size, by Country, 2017-2032 (USD Million)
TABLE 181. Global Stem Cells Market Size, by Region, 2017-2032 (USD Million)
TABLE 182. Global Stem Cells Market Size, by Group, 2017-2032 (USD Million)
TABLE 183. Global Stem Cells Market Size, by Country, 2017-2032 (USD Million)
TABLE 184. Global Hematopoietic Stem Cells Market Size, by Region, 2017-2032 (USD Million)
TABLE 185. Global Hematopoietic Stem Cells Market Size, by Group, 2017-2032 (USD Million)
TABLE 186. Global Hematopoietic Stem Cells Market Size, by Country, 2017-2032 (USD Million)
TABLE 187. Global Pluripotent Stem Cells Market Size, by Region, 2017-2032 (USD Million)
TABLE 188. Global Pluripotent Stem Cells Market Size, by Group, 2017-2032 (USD Million)
TABLE 189. Global Pluripotent Stem Cells Market Size, by Country, 2017-2032 (USD Million)
TABLE 190. Global Cellular & Gene Therapy CDMO Market Size, by Customer Type, 2017-2032 (USD Million)
TABLE 191. Global Academic And Research Institutions Market Size, by Region, 2017-2032 (USD Million)
TABLE 192. Global Academic And Research Institutions Market Size, by Group, 2017-2032 (USD Million)
TABLE 193. Global Academic And Research Institutions Market Size, by Country, 2017-2032 (USD Million)
TABLE 194. Global Clinical Treatment Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 195. Global Clinical Treatment Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 196. Global Clinical Treatment Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 197. Global Large Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 198. Global Large Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 199. Global Large Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 200. Global Small And Mid Size Biotech Market Size, by Region, 2017-2032 (USD Million)
TABLE 201. Global Small And Mid Size Biotech Market Size, by Group, 2017-2032 (USD Million)
TABLE 202. Global Small And Mid Size Biotech Market Size, by Country, 2017-2032 (USD Million)
TABLE 203. Global Cellular & Gene Therapy CDMO Market Size, by Therapy Indication, 2017-2032 (USD Million)
TABLE 204. Global Autoimmune And Inflammatory Market Size, by Region, 2017-2032 (USD Million)
TABLE 205. Global Autoimmune And Inflammatory Market Size, by Group, 2017-2032 (USD Million)
TABLE 206. Global Autoimmune And Inflammatory Market Size, by Country, 2017-2032 (USD Million)
TABLE 207. Global Cardiovascular Market Size, by Region, 2017-2032 (USD Million)
TABLE 208. Global Cardiovascular Market Size, by Group, 2017-2032 (USD Million)
TABLE 209. Global Cardiovascular Market Size, by Country, 2017-2032 (USD Million)
TABLE 210. Global Neurology Market Size, by Region, 2017-2032 (USD Million)
TABLE 211. Global Neurology Market Size, by Group, 2017-2032 (USD Million)
TABLE 212. Global Neurology Market Size, by Country, 2017-2032 (USD Million)
TABLE 213. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 214. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 215. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 216. Global Ophthalmology Market Size, by Region, 2017-2032 (USD Million)
TABLE 217. Global Ophthalmology Market Size, by Group, 2017-2032 (USD Million)
TABLE 218. Global Ophthalmology Market Size, by Country, 2017-2032 (USD Million)
TABLE 219. Global Rare Genetic Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 220. Global Rare Genetic Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 221. Global Rare Genetic Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 222. Global Cellular & Gene Therapy CDMO Market Size, by Region, 2017-2032 (USD Million)
TABLE 223. Asia-Pacific Cellular & Gene Therapy CDMO Market Size, by Region, 2017-2032 (USD Million)
TABLE 224. Asia-Pacific Cellular & Gene Therapy CDMO Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 225. Asia-Pacific Cellular & Gene Therapy CDMO Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 226. Asia-Pacific Cellular & Gene Therapy CDMO Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 227. Asia-Pacific Cellular & Gene Therapy CDMO Market Size, by Nucleic Acid Modalities, 2017-2032 (USD Million)
TABLE 228. Asia-Pacific Cellular & Gene Therapy CDMO Market Size, by Service Offering, 2017-2032 (USD Million)
TABLE 229. Asia-Pacific Cellular & Gene Therapy CDMO Market Size, by Analytical And Quality Control, 2017-2032 (USD Million)
TABLE 230. Asia-Pacific Cellular & Gene Therapy CDMO Market Size, by Cell Banking And Cryopreservation, 2017-2032 (USD Million)
TABLE 231. Asia-Pacific Cellular & Gene Therapy CDMO Market Size, by Fill Finish, 2017-2032 (USD Million)
TABLE 232. Asia-Pacific Cellular & Gene Therapy CDMO Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 233. Asia-Pacific Cellular & Gene Therapy CDMO Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 234. Asia-Pacific Cellular & Gene Therapy CDMO Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 235. Asia-Pacific Cellular & Gene Therapy CDMO Market Size, by Cell Culture Platforms, 2017-2032 (USD Million)
TABLE 236. Asia-Pacific Cellular & Gene Therapy CDMO Market Size, by Gene Editing Tools, 2017-2032 (USD Million)
TABLE 237. Asia-Pacific Cellular & Gene Therapy CDMO Market Size, by Non Viral Platforms, 2017-2032 (USD Million)
TABLE 238. Asia-Pacific Cellular & Gene Therapy CDMO Market Size, by Viral Vectors, 2017-2032 (USD Million)
TABLE 239. Asia-Pacific Cellular & Gene Therapy CDMO Market Size, by Cell Source, 2017-2032 (USD Million)
TABLE 240. Asia-Pacific Cellular & Gene Therapy CDMO Market Size, by Immune Cells, 2017-2032 (USD Million)
TABLE 241. Asia-Pacific Cellular & Gene Therapy CDMO Market Size, by Stem Cells, 2017-2032 (USD Million)
TABLE 242. Asia-Pacific Cellular & Gene Therapy CDMO Market Size, by Customer Type, 2017-2032 (USD Million)
TABLE 243. Asia-Pacific Cellular & Gene Therapy CDMO Market Size, by Therapy Indication, 2017-2032 (USD Million)
TABLE 244. North America Cellular & Gene Therapy CDMO Market Size, by Region, 2017-2032 (USD Million)
TABLE 245. North America Cellular & Gene Therapy CDMO Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 246. North America Cellular & Gene Therapy CDMO Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 247. North America Cellular & Gene Therapy CDMO Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 248. North America Cellular & Gene Therapy CDMO Market Size, by Nucleic Acid Modalities, 2017-2032 (USD Million)
TABLE 249. North America Cellular & Gene Therapy CDMO Market Size, by Service Offering, 2017-2032 (USD Million)
TABLE 250. North America Cellular & Gene Therapy CDMO Market Size, by Analytical And Quality Control, 2017-2032 (USD Million)
TABLE 251. North America Cellular & Gene Therapy CDMO Market Size, by Cell Banking And Cryopreservation, 2017-2032 (USD Million)
TABLE 252. North America Cellular & Gene Therapy CDMO Market Size, by Fill Finish, 2017-2032 (USD Million)
TABLE 253. North America Cellular & Gene Therapy CDMO Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 254. North America Cellular & Gene Therapy CDMO Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 255. North America Cellular & Gene Therapy CDMO Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 256. North America Cellular & Gene Therapy CDMO Market Size, by Cell Culture Platforms, 2017-2032 (USD Million)
TABLE 257. North America Cellular & Gene Therapy CDMO Market Size, by Gene Editing Tools, 2017-2032 (USD Million)
TABLE 258. North America Cellular & Gene Therapy CDMO Market Size, by Non Viral Platforms, 2017-2032 (USD Million)
TABLE 259. North America Cellular & Gene Therapy CDMO Market Size, by Viral Vectors, 2017-2032 (USD Million)
TABLE 260. North America Cellular & Gene Therapy CDMO Market Size, by Cell Source, 2017-2032 (USD Million)
TABLE 261. North America Cellular & Gene Therapy CDMO Market Size, by Immune Cells, 2017-2032 (USD Million)
TABLE 262. North America Cellular & Gene Therapy CDMO Market Size, by Stem Cells, 2017-2032 (USD Million)
TABLE 263. North America Cellular & Gene Therapy CDMO Market Size, by Customer Type, 2017-2032 (USD Million)
TABLE 264. North America Cellular & Gene Therapy CDMO Market Size, by Therapy Indication, 2017-2032 (USD Million)
TABLE 265. Latin America Cellular & Gene Therapy CDMO Market Size, by Region, 2017-2032 (USD Million)
TABLE 266. Latin America Cellular & Gene Therapy CDMO Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 267. Latin America Cellular & Gene Therapy CDMO Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 268. Latin America Cellular & Gene Therapy CDMO Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 269. Latin America Cellular & Gene Therapy CDMO Market Size, by Nucleic Acid Modalities, 2017-2032 (USD Million)
TABLE 270. Latin America Cellular & Gene Therapy CDMO Market Size, by Service Offering, 2017-2032 (USD Million)
TABLE 271. Latin America Cellular & Gene Therapy CDMO Market Size, by Analytical And Quality Control, 2017-2032 (USD Million)
TABLE 272. Latin America Cellular & Gene Therapy CDMO Market Size, by Cell Banking And Cryopreservation, 2017-2032 (USD Million)
TABLE 273. Latin America Cellular & Gene Therapy CDMO Market Size, by Fill Finish, 2017-2032 (USD Million)
TABLE 274. Latin America Cellular & Gene Therapy CDMO Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 275. Latin America Cellular & Gene Therapy CDMO Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 276. Latin America Cellular & Gene Therapy CDMO Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 277. Latin America Cellular & Gene Therapy CDMO Market Size, by Cell Culture Platforms, 2017-2032 (USD Million)
TABLE 278. Latin America Cellular & Gene Therapy CDMO Market Size, by Gene Editing Tools, 2017-2032 (USD Million)
TABLE 279. Latin America Cellular & Gene Therapy CDMO Market Size, by Non Viral Platforms, 2017-2032 (USD Million)
TABLE 280. Latin America Cellular & Gene Therapy CDMO Market Size, by Viral Vectors, 2017-2032 (USD Million)
TABLE 281. Latin America Cellular & Gene Therapy CDMO Market Size, by Cell Source, 2017-2032 (USD Million)
TABLE 282. Latin America Cellular & Gene Therapy CDMO Market Size, by Immune Cells, 2017-2032 (USD Million)
TABLE 283. Latin America Cellular & Gene Therapy CDMO Market Size, by Stem Cells, 2017-2032 (USD Million)
TABLE 284. Latin America Cellular & Gene Therapy CDMO Market Size, by Customer Type, 2017-2032 (USD Million)
TABLE 285. Latin America Cellular & Gene Therapy CDMO Market Size, by Therapy Indication, 2017-2032 (USD Million)
TABLE 286. Europe Cellular & Gene Therapy CDMO Market Size, by Region, 2017-2032 (USD Million)
TABLE 287. Europe Cellular & Gene Therapy CDMO Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 288. Europe Cellular & Gene Therapy CDMO Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 289. Europe Cellular & Gene Therapy CDMO Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 290. Europe Cellular & Gene Therapy CDMO Market Size, by Nucleic Acid Modalities, 2017-2032 (USD Million)
TABLE 291. Europe Cellular & Gene Therapy CDMO Market Size, by Service Offering, 2017-2032 (USD Million)
TABLE 292. Europe Cellular & Gene Therapy CDMO Market Size, by Analytical And Quality Control, 2017-2032 (USD Million)
TABLE 293. Europe Cellular & Gene Therapy CDMO Market Size, by Cell Banking And Cryopreservation, 2017-2032 (USD Million)
TABLE 294. Europe Cellular & Gene Therapy CDMO Market Size, by Fill Finish, 2017-2032 (USD Million)
TABLE 295. Europe Cellular & Gene Therapy CDMO Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 296. Europe Cellular & Gene Therapy CDMO Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 297. Europe Cellular & Gene Therapy CDMO Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 298. Europe Cellular & Gene Therapy CDMO Market Size, by Cell Culture Platforms, 2017-2032 (USD Million)
TABLE 299. Europe Cellular & Gene Therapy CDMO Market Size, by Gene Editing Tools, 2017-2032 (USD Million)
TABLE 300. Europe Cellular & Gene Therapy CDMO Market Size, by Non Viral Platforms, 2017-2032 (USD Million)
TABLE 301. Europe Cellular & Gene Therapy CDMO Market Size, by Viral Vectors, 2017-2032 (USD Million)
TABLE 302. Europe Cellular & Gene Therapy CDMO Market Size, by Cell Source, 2017-2032 (USD Million)
TABLE 303. Europe Cellular & Gene Therapy CDMO Market Size, by Immune Cells, 2017-2032 (USD Million)
TABLE 304. Europe Cellular & Gene Therapy CDMO Market Size, by Stem Cells, 2017-2032 (USD Million)
TABLE 305. Europe Cellular & Gene Therapy CDMO Market Size, by Customer Type, 2017-2032 (USD Million)
TABLE 306. Europe Cellular & Gene Therapy CDMO Market Size, by Therapy Indication, 2017-2032 (USD Million)
TABLE 307. Middle East Cellular & Gene Therapy CDMO Market Size, by Region, 2017-2032 (USD Million)
TABLE 308. Middle East Cellular & Gene Therapy CDMO Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 309. Middle East Cellular & Gene Therapy CDMO Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 310. Middle East Cellular & Gene Therapy CDMO Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 311. Middle East Cellular & Gene Therapy CDMO Market Size, by Nucleic Acid Modalities, 2017-2032 (USD Million)
TABLE 312. Middle East Cellular & Gene Therapy CDMO Market Size, by Service Offering, 2017-2032 (USD Million)
TABLE 313. Middle East Cellular & Gene Therapy CDMO Market Size, by Analytical And Quality Control, 2017-2032 (USD Million)
TABLE 314. Middle East Cellular & Gene Therapy CDMO Market Size, by Cell Banking And Cryopreservation, 2017-2032 (USD Million)
TABLE 315. Middle East Cellular & Gene Therapy CDMO Market Size, by Fill Finish, 2017-2032 (USD Million)
TABLE 316. Middle East Cellular & Gene Therapy CDMO Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 317. Middle East Cellular & Gene Therapy CDMO Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 318. Middle East Cellular & Gene Therapy CDMO Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 319. Middle East Cellular & Gene Therapy CDMO Market Size, by Cell Culture Platforms, 2017-2032 (USD Million)
TABLE 320. Middle East Cellular & Gene Therapy CDMO Market Size, by Gene Editing Tools, 2017-2032 (USD Million)
TABLE 321. Middle East Cellular & Gene Therapy CDMO Market Size, by Non Viral Platforms, 2017-2032 (USD Million)
TABLE 322. Middle East Cellular & Gene Therapy CDMO Market Size, by Viral Vectors, 2017-2032 (USD Million)
TABLE 323. Middle East Cellular & Gene Therapy CDMO Market Size, by Cell Source, 2017-2032 (USD Million)
TABLE 324. Middle East Cellular & Gene Therapy CDMO Market Size, by Immune Cells, 2017-2032 (USD Million)
TABLE 325. Middle East Cellular & Gene Therapy CDMO Market Size, by Stem Cells, 2017-2032 (USD Million)
TABLE 326. Middle East Cellular & Gene Therapy CDMO Market Size, by Customer Type, 2017-2032 (USD Million)
TABLE 327. Middle East Cellular & Gene Therapy CDMO Market Size, by Therapy Indication, 2017-2032 (USD Million)
TABLE 328. Africa Cellular & Gene Therapy CDMO Market Size, by Region, 2017-2032 (USD Million)
TABLE 329. Africa Cellular & Gene Therapy CDMO Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 330. Africa Cellular & Gene Therapy CDMO Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 331. Africa Cellular & Gene Therapy CDMO Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 332. Africa Cellular & Gene Therapy CDMO Market Size, by Nucleic Acid Modalities, 2017-2032 (USD Million)
TABLE 333. Africa Cellular & Gene Therapy CDMO Market Size, by Service Offering, 2017-2032 (USD Million)
TABLE 334. Africa Cellular & Gene Therapy CDMO Market Size, by Analytical And Quality Control, 2017-2032 (USD Million)
TABLE 335. Africa Cellular & Gene Therapy CDMO Market Size, by Cell Banking And Cryopreservation, 2017-2032 (USD Million)
TABLE 336. Africa Cellular & Gene Therapy CDMO Market Size, by Fill Finish, 2017-2032 (USD Million)
TABLE 337. Africa Cellular & Gene Therapy CDMO Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 338. Africa Cellular & Gene Therapy CDMO Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 339. Africa Cellular & Gene Therapy CDMO Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 340. Africa Cellular & Gene Therapy CDMO Market Size, by Cell Culture Platforms, 2017-2032 (USD Million)
TABLE 341. Africa Cellular & Gene Therapy CDMO Market Size, by Gene Editing Tools, 2017-2032 (USD Million)
TABLE 342. Africa Cellular & Gene Therapy CDMO Market Size, by Non Viral Platforms, 2017-2032 (USD Million)
TABLE 343. Africa Cellular & Gene Therapy CDMO Market Size, by Viral Vectors, 2017-2032 (USD Million)
TABLE 344. Africa Cellular & Gene Therapy CDMO Market Size, by Cell Source, 2017-2032 (USD Million)
TABLE 345. Africa Cellular & Gene Therapy CDMO Market Size, by Immune Cells, 2017-2032 (USD Million)
TABLE 346. Africa Cellular & Gene Therapy CDMO Market Size, by Stem Cells, 2017-2032 (USD Million)
TABLE 347. Africa Cellular & Gene Therapy CDMO Market Size, by Customer Type, 2017-2032 (USD Million)
TABLE 348. Af

Companies Mentioned

  • AGC Biologics A/S
  • BioCentriq, Inc.
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • Cellares Corporation
  • Cellipont Bioservices, LLC
  • Charles River Laboratories International, Inc.
  • ElevateBio, Inc.
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • GenScript ProBio, Inc.
  • Kincell Bio, LLC
  • Lonza Group AG
  • Minaris Regenerative Medicine GmbH
  • National Resilience, Inc.
  • Oxford BioMedica plc
  • Porton Advanced Solutions Ltd.
  • Samsung Biologics Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • VectorBuilder Inc.
  • WuXi Advanced Therapies Inc.
  • WuXi AppTec Co., Ltd.

Related Topics

Related Reports

Advanced Therapy Medicinal Products CDMO Market - Global Forecast 2026-2032 - Product Image

Advanced Therapy Medicinal Products CDMO Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Cell & Gene Therapy Biomanufacturing CDMO Market - Global Forecast 2026-2032 - Product Image

Cell & Gene Therapy Biomanufacturing CDMO Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Viral Vector & Plasmid DNA Manufacturing Market - Global Forecast 2026-2032 - Product Image

Viral Vector & Plasmid DNA Manufacturing Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Plasmid CDMO Services Market - Global Forecast 2026-2032 - Product Image

Plasmid CDMO Services Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Plasmid DNA CDMO Service Market - Global Forecast 2026-2032 - Product Image

Plasmid DNA CDMO Service Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.